BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, March 21, 2026
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
March 27, 2002
View Archived Issues
Amrad’s Stock Falls On Poor Phase II Results For Emfilermin
Read More
New Gene Inhibition Technique Aims To Hasten Gene Analysis
Read More
Schering To Purchase Collateral For $140M In Stock Exchange
Read More
Millennium, Compugen In Deal For Protein Pathway Software
Read More
Cyclacel, University Of Edinburgh Form Drug Design Collaboration
Read More
Avidex Platform Creates TCRs; Company Planning Partnerships
Read More
U.S. Research Foundation Backs Swedish Stem Cell Program
Read More
ReGen’s Phase IIa Interim Data Not Significant In Alzheimer’s
Read More
Other News To Note
Read More
Vernalis Seeks Second Nasdaq Listing, Reports Profitability
Read More
J&J Buying Tibotec-Virco For $320 In Cash And Debt
PARIS Johnson & Johnson signed a definitive agreement to acquire all of the assets of Tibotec-Virco NV for $320 million in cash and debt. (BioWorld International)
Read More
